Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Anaplastic thyroid carcinoma (ATC) is a highly aggressive and lethal human neoplasm with limited therapeutic options.
• Overexpression of oncogenic proteins HMGA1 and EZH2 has been identified as crucial in ATC progression.

Purpose of the Study:

• To investigate the therapeutic potential of targeting HMGA1 with trabectedin and EZH2 with GSK126 in ATC.
• To evaluate the efficacy of these drugs, individually and in combination, on ATC cell viability and identify their molecular targets.

Main Methods:

• Confirmation of HMGA1 and EZH2 overexpression in ATC cell lines and tissues.
• Treatment of ATC cell lines with trabectedin and GSK126, both alone and in combination.
• Assessment of cell viability and induction of apoptotic cell death.
• Analysis of gene expression changes in HMGA1- and EZH2-controlled pathways.

Main Results:

• Both trabectedin and GSK126 significantly reduced ATC cell viability by inducing apoptosis.
• Combination therapy with trabectedin and GSK126 demonstrated a synergistic effect, leading to increased cell death.
• Normal thyroid cells showed no significant viability reduction upon drug treatment.
• Both drugs effectively deregulated genes controlled by EZH2 and HMGA1.

Conclusions:

• The combination of trabectedin and GSK126 presents a promising novel therapeutic strategy for anaplastic thyroid carcinoma.
• Targeting both HMGA1 and EZH2 pathways offers a selective approach to treating ATC with minimal toxicity to normal cells.